Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer

The purpose of this study was to evaluate the efficacy and safety of docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Thirty-four patients with advanced NSCLC received docetaxel 75 mg/m2 (1-h intravenous infusion) every 3 weeks, with corticosteroid premedication...

Full description

Saved in:
Bibliographic Details
Main Authors: Thongprasert S., Cheewakriangkrai R., Napapan S.
Format: Article
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-0036985870&partnerID=40&md5=c9ee0ff44844ea8301aa32e0149fdcbf
http://www.ncbi.nlm.nih.gov/pubmed/12678167
http://cmuir.cmu.ac.th/handle/6653943832/2100
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English